| Trial ID: | L2850 |
| Source ID: | NCT01165268
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin, Before 7 days of oral administration of 10 mg of dapagliflozin|The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin, After 7 days of oral administration of 10 mg of dapagliflozin | Secondary: Splay of the glucose titration curve, Before 7 days of oral administration of 10 mg of dapagliflozin|Splay of the glucose titration curve, After 7 days of oral administration of 10 mg of dapagliflozin|Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin, Study Day 7|Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin, Study Day 8
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2010-08
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-17
|
| Locations: |
Profil Institute For Clinical Research, Inc., Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01165268
|
